Cardiovascular events, including ischemic heart disease, cerebrovascular disease, and peripheral artery disease, are major concerns in patients with CML, particularly in those under treatment with second- and third-generation Bcr-ABL TKIs nilotinib and ponatinib, respectively (14). The gene discussed is ABL1; the disease is coronary artery disorder.